Table 2.

Estimated ΔΔQTcF Values of the Effect of Cabotegravir and Moxifloxacin on QTcF Interval in Healthy Subjects

	Cabotegravir 150 mg Every
	12 Hours × 3 Doses		Moxifloxacin 400 mg
Time Point (h)	ΔΔQTcF (ms),a mean ± SE	90%CI	ΔΔQTcF (ms),b mean ± SE	90%CI
0.5	0.70 ± 2.00	−2.62, 4.02	5.40 ± 2.05	2.00–8.81
1	−0.37 ± 1.74	−3.26, 2.53	8.75 ± 1.79	5.78–11.71
2	0.44 ± 1.83	−2.61, 3.48	11.67 ± 1.88	8.55–14.79
3	−0.62 ± 1.69	−3.43, 2.19	10.49 ± 1.73	7.60–13.37
4	−0.37 ± 1.53	−2.91, 2.17	11.81 ± 1.57	9.20–14.42
6.5	0.50 ± 1.63	−2.21, 3.22	10.08 ± 1.68	7.29–12.86
8	2.62 ± 1.59	−0.02, 5.26	13.03 ± 1.63	10.32–15.74
12	−0.34 ± 1.66	−3.10, 2.42	7.79 ± 1.69	4.98–10.60
24	1.13 ± 2.05	−2.27, 4.53	6.53 ± 2.10	3.04–10.02

Note: Lack of effect is demonstrated if the upper limit of the 90%CI (95th percentile) for cabotegravir–placebo at each time is completely contained within 10 ms.

ΔΔQTcF, change from baseline in QTcF between each active treatment relative to placebo; CI, confidence interval; QTcF, corrected QT interval using Fridericia's formula; SE, standard error.

^aChange from baseline of (cabotegravir–placebo).

^bChange from baseline of (moxifloxacin–placebo).